News articles about Actinium Pharmaceuticals (NYSEMKT:ATNM) have been trending positive on Friday, Alpha One Sentiment reports. Alpha One, a division of Accern, ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Actinium Pharmaceuticals earned a daily sentiment score of 0.34 on Alpha One’s scale. Alpha One also gave media stories about the biotechnology company an impact score of 43 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have effected AlphaOne Sentiment Analysis’s analysis:
- Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) 2016 Q4 Sentiment – KL Daily (kldaily.com)
- Both Teva Pharmaceutical Industries Limited (TEVA) And Actinium Pharmaceuticals, Inc. (ATNM) Grabbing Attentions … – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Actinium Pharma (ATNM) Publishes Letter to Shareholders Highlighting Accomplishments & Upcoming Catalysts – StreetInsider.com (streetinsider.com)
- Stocks Views And Recommendations: Zosano Pharma Corporation (NASDAQ:ZSAN), Actinium Pharmaceuticals, Inc … – AllStockNews (allstocknews.com)
- Actinium Pharma (ATNM) Appoints Nitya Ray Ph.D. as EVP, Head of … – StreetInsider.com (streetinsider.com)
Shares of Actinium Pharmaceuticals (ATNM) traded down 2.61% during mid-day trading on Friday, reaching $1.12. The company had a trading volume of 376,701 shares. The stock has a 50 day moving average of $1.39 and a 200-day moving average of $1.29. Actinium Pharmaceuticals has a one year low of $0.86 and a one year high of $2.15. The firm’s market capitalization is $65.46 million.
ATNM has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, May 8th. Zacks Investment Research downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday.
ILLEGAL ACTIVITY NOTICE: This story was first posted by sleekmoney and is owned by of sleekmoney. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://sleekmoney.com/positive-media-coverage-somewhat-unlikely-to-affect-actinium-pharmaceuticals-atnm-share-price/1916657.html.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/positive-media-coverage-somewhat-unlikely-to-affect-actinium-pharmaceuticals-atnm-share-price/1916657.html
Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.